Pathology and Lab Medicine

Episodes 1-15 of 56

• 

  RestartResume

  HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

  Project Oncology®

  HER2 Testing: The Evolving Role of Immunohistochemistry (IHC)

  • 

    

    Fernando López-Ríos, MD, PhD

    Peer

  • 

    

    Christian Rolfo, MD, PhD

    Peer

  • 

    

    Charlie Gourley, MD, PhD

    Peer

• 

  MinuteCE®

  The Pathologist Perspective: Identifying Systemic Mastocytosis in the Community

  • 

    

    Nathan A. Boggs, MD

    Peer

  • 

    

    Tracy George, MD

    Peer

  • 

    

    Lindsay Rein, MD

    Peer

  0.50 credits 4 episodes

• 

  RestartResume

  Differential Diagnosis of Indolent Systemic Mastocytosis

  MinuteCE®

  Differential Diagnosis of Indolent Systemic Mastocytosis

  • 

    

    Nathan A. Boggs, MD

    Peer

  • 

    

    Tracy George, MD

    Peer

  • 

    

    Lindsay Rein, MD

    Peer

  0.50 program credits

• 

  RestartResume

  Is it Nonresponsive/Progressive ISM?

  MinuteCE®

  Is it Nonresponsive/Progressive ISM?

  • 

    

    Nathan A. Boggs, MD

    Peer

  • 

    

    Tracy George, MD

    Peer

  • 

    

    Lindsay Rein, MD

    Peer

  0.50 program credits

• 

  RestartResume

  Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

  MinuteCE®

  Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

  • 

    

    Nathan A. Boggs, MD

    Peer

  • 

    

    Tracy George, MD

    Peer

  • 

    

    Lindsay Rein, MD

    Peer

  0.50 program credits

• 

  RestartResume

  Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia

  MinuteCE®

  Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia

  • 

    

    Nathan A. Boggs, MD

    Peer

  • 

    

    Tracy George, MD

    Peer

  • 

    

    Lindsay Rein, MD

    Peer

  0.50 program credits

• 

  MinuteCE®

  Decoding ANCA-Associated Vasculitis (AAV): From Suspicion to Solution

  • 

    

    Bernhard Hellmich, MD

    Peer

  • 

    

    Andreas Kronbichler, MD

    Peer

  • 

    

    Silke R. Brix, MD, MRCP, SCPR

    Peer

  0.75 credits 6 episodes

• 

  RestartResume

  Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor

  MinuteCE®

  Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor

  • 

    

    Seema A. Bhat, MD

    Peer

  • 

    

    Jeremy S. Abramson, MD, MMSc

    Peer

  0.50 program credits

• 

  RestartResume

  Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies

  MinuteCE®

  Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies

  • 

    

    Seema A. Bhat, MD

    Peer

  • 

    

    Jeremy S. Abramson, MD, MMSc

    Peer

  0.50 program credits

• 

  RestartResume

  Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy

  MinuteCE®

  Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy

  • 

    

    Seema A. Bhat, MD

    Peer

  • 

    

    Jeremy S. Abramson, MD, MMSc

    Peer

  0.50 program credits

• 

  RestartResume

  Emerging data with potentially guideline-changing implications in CLL/SLL and MCL

  MinuteCE®

  Emerging data with potentially guideline-changing implications in CLL/SLL and MCL

  • 

    

    Seema A. Bhat, MD

    Peer

  • 

    

    Jeremy S. Abramson, MD, MMSc

    Peer

  0.50 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 credits 10 episodes

• 

  RestartResume

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  MinuteCE®

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 1
• 2
• 3
• 4
• Next